Meeting
2020 Genitourinary Cancers Symposium
Cost-effectiveness of upfront therapeutic options in low-volume de novo metastatic hormone-sensitive prostate cancer.
Authors
Neil Rohit Parikh
Baylor Coll of Medcn, Houston, TX
Neil Rohit Parikh , Eric M. Chang , Nicholas George Nickols , Matthew Rettig , Ann C. Raldow , Michael L. Steinberg , Bridget F. Koontz , Neha Vapiwala , Curtiland Deville , Felix Y Feng , Daniel Eidelberg Spratt , Robert Evan Reiter , Ryan Phillips , Phuoc T. Tran , Amar Upadhyaya Kishan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Other
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr 211)
Abstract #
211
Poster Bd #
K5
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Apalutamide and stereotactic body radiation therapy for low-burden, metastatic, hormone-sensitive prostate cancer: A randomized trial (PERSIAN).
First Author: Giulio Francolini
Poster
2023 ASCO Genitourinary Cancers Symposium
Cost-effectiveness analysis of seven treatment regimens in metastatic hormone-sensitive prostate cancer (mHSPC): A public payer perspective using network meta-analysis.
First Author: Manish Kohli
Poster
2023 ASCO Genitourinary Cancers Symposium
Cost-effectiveness of abiraterone acetate for high-risk nnon-metastatic prostate cancer.
First Author: Nataniel Hernan Lester-Coll
Poster
2024 ASCO Genitourinary Cancers Symposium
Cost-effectiveness of triplet therapies in metastatic hormone-sensitive prostate cancer used in PEACE-1 and ARASENS.
First Author: Nataniel Hernan Lester-Coll